|
 |
imiglucerase forThis page contains recent news articles, when available, and an overview of imiglucerase for but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Commission filing, Genzyme revealed that Hospira will perform 'fill and finish' manufacturing services for Cerezyme (imiglucerase) for Gaucher disease, ... Pharma Times Guru Stocks at 52-Week Low: Genzyme Corp, Huaneng Power International Inc ... - Jan 2, 2010 Results reflect the impact of the temporary interruption in production of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) associated ... GuruFocus.com Shire requests FDA approval of Fabry disease drug - Dec 23, 2009 Genzyme's manufacturing problems also led to a shortage of Cerezyme (imiglucerase) for Gaucher disease and Shire's bid to fill the void is making progress. ... Pharma Times Genzyme Issues Letters to US Healthcare Providers - Nov 13, 2009 ...(Nasdaq: GENZ) announced today that it has issued letters to US healthcare providers regarding its enzyme replacement products Cerezyme ® (imiglucerase for ... WELT ONLINE Genzyme Corporation - SWOT Analysis - New Report Published - Nov 12, 2009 The increase was primarily due to higher sales of Cerezyme ((imiglucerase for injection), Fabrazyme (agalsidase beta), Renagel (sevelamer hydrochloride), ... OfficialWire (press release) Genzyme production in 'recovery mode' - Oct 22, 2009 Cerezyme (imiglucerase) for Gaucher disease and Fabrazyme (agalsidase beta) for Fabry disease, restarting next month and in December, respectively. ... Pharmafocus FDA OKs Shire's Replagal treatment protocol; BLA filing soon - Oct 22, 2009 ...shortage of Fabrazyme (agalsidase beta) - the only marketed Fabry disease drug in the US - as well as Cerezyme (imiglucerase) for Gaucher disease. ... Pharma Times Genzyme Releases 3Q Financial Results - Oct 26, 2009 In a release on October 21, the Company noted that results reflect the impact of the temporary interruption in production of Cerezyme (imiglucerase for ... Trading Markets (press release) Genzyme Begins Enrollment in Phase 3 Trials of Oral Capsule for Gaucher Disease - Oct 23, 2009 Encore is a randomized, open-label study for adult patients with Gaucher disease type 1 designed to compare Genz-112638 to Cerezyme (imiglucerase for ... Trading Markets (press release) Genzyme Reports Third-Quarter Financial Results - Oct 22, 2009 Results reflect the impact of the temporary interruption in production of Cerezyme ® (imiglucerase for injection) and Fabrazyme ® (agalsidase beta) ... Business Wire (press release) Genzyme Announces Publication of Study Showing Impact of Cerezyme … - Jan 15, 2007 Cerezyme (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of ... webwire.com Genzyme Announces Publication Of Study Showing Impact Of Cerezyme … - Jan 16, 2007 Cerezyme (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of ... Medical News Today - Medical News Today (press release) Imiglucerase (Systemic). - Feb 1, 2006 You may have to receive imiglucerase for the rest of your life. If Gaucher's disease is not treated, it can cause serious blood, liver, skeletal, ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Press Release: Genzyme Announces Publication of Study Showing … - Jan 15, 2007 Cerezyme (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of ... Pay-Per-View - PR Newswire - HighBeam Research Epo, by any other name - Sep 20, 2007 Regulators must be given ways to approve follow-on 'biosimilars' when proteins fall out of patent if the fruits of molecular biology are to have the ... Nature.com Genzyme Expands its Research and Manufacturing Presence in … - Oct 5, 2005 Two of Genzyme's major products are currently produced at Allston: Cerezyme® (imiglucerase for injection), an enzyme replacement therapy for Type 1 Gaucher ... webwire.com Genzyme Reports Financial Results for the First Quarter of 2006. - Apr 19, 2006 Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $239.0 million compared with $226.0 million in ... Free with registration - PR Newswire - AccessMyLibrary.com Issues Updates on Genzyme Corp. - Jul 12, 2006 Sales of Cerezyme (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $254.0 million, 8 percent greater than sales of ... Free with registration - M2 Presswire - AccessMyLibrary.com Novel Oral Compound Has Potential For Gaucher Disease - May 9, 2008 Genzyme's Cerezyme (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous ... emaxhealth.com Amicus Therapeutics Presents Positive Data From Phase 2 Clinical... - Mar 14, 2008 Patients were on enzyme replacement therapy (ERT) with imiglucerase for an average of 9 years prior to entering the trial, and they temporarily discontinued ... Medical News Today - Medical News Today (press release) Fosrenol's Threat To Renagel May Be Leveling Off: Report - Apr 18, 2005 By Randall Osborne. Earlier this month, powerhouse Genzyme Corp. disclosed its launch of Phase III trials with the toxin binder tolevamer for patients with ... BioWorld Online - BioWorld Online Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Sales of Cerezyme® (imiglucerase for injection) are expected to reach $970-$980 million this year, compared with $932 million in 2005. ... webwire.com Genzyme Corporation Reports Strong Growth in Second Quarter 2008 - Jul 24, 2008 Second-quarter Cerezyme® (imiglucerase for injection) sales rose 13 percent to $319.4 million, compared with $283.0 million in the previous second quarter. ... allamericanpatriots.com Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full... - Feb 14, 2007 Sales of Cerezyme® (imiglucerase for injection) are expected to reach $1.060-$1.075 billion this year, compared with $1.0 billion in 2006. ... webwire.com Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Sales of Cerezyme(R) (imiglucerase for injection) are expected to reach $970-$980 million this year, compared with $932 million in 2005. ... $4.95 - PR Newswire - ECNext Genzyme Delivers Excellent Fourth-Quarter and 2004 Performance ------... - Feb 17, 2005 Sales of Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease will continue to grow but will become a smaller percentage of revenue once ... $4.95 - PR Newswire - ECNext Genzyme invests another EUR 130m in Irish facility - Apr 7, 2008 The expansion is to meet increased demand for the company's biological products such as the Gaucher Disease treatment Cerezyme (imiglucerase for injection), ... In-PharmaTechnologist.com Genzyme Receives Approval for Additional Manufacturing at Ireland... - Jul 24, 2006 Genzyme is currently conducting approval-qualifying manufacturing runs of Cerezyme(R) (imiglucerase for injection) and Myozyme(R) (alglucosidase alfa) at ... Free with registration - PR Newswire - AccessMyLibrary.com Preliminary Results From Phase 2 Genzyme Study Highlight Potential Of... - May 8, 2008 Genzyme's Cerezyme(R) (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous ... Medical News Today - Medical News Today (press release) Genzyme Delivers Strong Third-Quarter Results. - Oct 18, 2005 Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $238.3 million compared with $208.4 million in ... $4.95 - PR Newswire - ECNext Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude … - Jan 9, 2007 Fourth-quarter sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $262 million, 13 percent greater ... webwire.com Genzyme Launches Initiative to Assist the Development of Treatments... - Apr 10, 2006 Among the programs Genzyme sponsors is the Gaucher Initiative, a partnership with Project HOPE that brings Cerezyme(R) (imiglucerase for injection) therapy ... Free with registration - PR Newswire - AccessMyLibrary.com Article: Genzyme files suit against TKT for glucocerebrosidase patent... - Jan 1, 2005 Genzyme's patent covers novel culture processes that have been critical in enabling the company to produce Cerezyme (imiglucerase for injection) on a large ... Pay-Per-View - BIOTECH Patent News - HighBeam Research Genzyme to Build New R&D Center in Beijing - Apr 24, 2008 Since 1999, Genzyme has provided its rare genetic disease treatment Cerezyme® (imiglucerase for injection) free of charge to Chinese patients in need. ... webwire.com Genzyme Reports Significant Earnings Growth in Second Quarter - Jul 26, 2007 Sales of Cerezyme® (imiglucerase for injection) grew 11 percent to $283.0 million, compared with $254.0 million in the second quarter a year ago. ... webwire.com Genzyme $57.3M net loss for 4th qtr 2004. - Feb 28, 2005 ...and the firm anticipates that sales of Cerezyme (imiglucerase for injection) for Type 1 Gaucher disease will continue to grow, reaching $870.0-$890.0 ... $4.95 - Pharma Marketletter - ECNext First Therapy Ever Approved in Canada for Ultra-Rare Form of Muscular... - Dec 8, 2006 MISSISSAUGA, ON, CANADA -- December 8, 2006 -- Following the August 2006 approval by Health Canada, Genzyme Canada today announced the availability of ... DG News Genzyme's 4th-qtr sales climb 21%, beating forecasts; predicts EPS of... - Jan 21, 2008 ...sales of which rose 18% to $114.0 million; Cerezyme (imiglucerase for injection), for Gaucher's disease, which contributed $301.0 million, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Genzyme Begins $150 Million Expansion of Boston Manufacturing Facility - Sep 19, 2007 ...and the facility was initially intended to produce one product -- Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease. ... Boston/SF Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS … - Jul 14, 2005 Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $236.0 million in the second quarter, ... $4.95 - PR Newswire - ECNext Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue - Jan 9, 2006 Fourth-quarter sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $232 million, 6 percent greater ... webwire.com Genzyme Reports Strong Fourth-Quarter Revenue Growth. - Jan 11, 2005 Sales of Cerezyme(R) (imiglucerase for injection), an enzyme replacement therapy for patients with Type 1 Gaucher disease, were $219 million in the fourth ... $4.95 - PR Newswire - ECNext Press Release: Preliminary Results from Phase 2 Genzyme Study … - May 7, 2008 Genzyme's Cerezyme(R) (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous ... Pay-Per-View - PR Newswire - HighBeam Research LSD Deal Brings Amicus $50M Now, $390M Later - Nov 9, 2007 Genzyme's Fabry disease drug Fabrazyme (agalsidase beta) brought in $104.6 million, while its Gaucher disease drug Cerezyme (imiglucerase for injection) ... BioWorld Online - BioWorld Online Genzyme's Myozyme Gets FDA Clearance For Pompe.(enzyme- … - May 1, 2006 Already on the market are Cerezyme (imiglucerase for injection) for Type I Gaucher's disease, Fabrazyme (agalsidase beta) for Fabry's disease and Aldurazyme ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Genzyme files suit against TKT for glucocerebrosidase patent … - Jan 1, 2005 Genzyme's patent covers novel culture processes that have been critical in enabling the company to produce Cerezyme (imiglucerase for injection) on a large ... $4.95 - BIOTECH Patent News - ECNext Press Release: Genzyme to Build New R&D Center in Beijing. - PR … - Apr 22, 2008 Since 1999, Genzyme has provided its rare genetic disease treatment Cerezyme(R) (imiglucerase for injection) free of charge to Chinese patients in need. ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme given green light to make kidney drug at Irish plant - Aug 14, 2006 Genzyme said it also plans to use the Waterford facility for additional capacity and security for the fill/finish of Cerezyme (imiglucerase for injection) ... In-PharmaTechnologist.com Genzyme Reports Growth in First Quarter. - Apr 25, 2007 Sales of Cerezyme (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, grew 10 percent to $263.8 million, ... $4.95 - M2 Presswire - ECNext Genzyme files Glucocerebrosidase patent infringement - Jan 25, 2005 Genzyme's patent covers novel culture processes that have been critical in enabling the company to produce Cerezyme(R) (imiglucerase for injection) on a ... News-Medical.net Press Release: Genzyme Expands Global Infrastructure for Manufacturing... - Sep 22, 2005 ...ongoing ... compound to become an innovative treatment option for Gaucher disease. Genzyme's Cerezyme(R) (imiglucerase for injection), the standard of . ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme's 3rd-quarter net profit falls 86% on higher costs, despite... - Oct 23, 2006 ...and the Gaucher disease treatment Cerezyme (imiglucerase for injection), which contributed $252.2 million in sales, up 6% in the quarter. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Strong third quarter for Genzyme: GAAP net income reaches $159M on … - Nov 5, 2007 Strong third quarter for Genzyme: GAAP net income reaches $159M on the back of good sales. US biotechnology major Genzyme's third-quarter 2007 profit was ... $9.94 - Pharma Marketletter - Alacra Store Genzyme's 1st-qtr revenues jump 25%. - May 5, 2008 Turnover of Cerezyme (imiglucerase for injection), for Gaucher's disease, rose 15% to $304.3 million, while income from Fabrazyme (agalsidase beta) grew 16% ... $9.94 - Pharma Marketletter - Alacra Store Press Release: Genzyme Announces Publication in PNAS Describing … - May 22, 2007 Genzyme developed and now provides four enzyme replacement therapies for lysosomal storage disorders including Cerezyme(R) (imiglucerase for injection) for ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme's 2nd-qtr 2006 revenue rises 19%. - Jul 24, 2006 The USA's Genzyme Corp reported second-quarter 2006 revenue of $793.4 million, a 19% increase on the like, year-ago period, driven by growth across all ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Genzyme's 2nd qtr profit hit by license cost. - Aug 4, 2008 Genzyme's 2nd qtr profit hit by license cost. US biotechnology major Genzyme's second-quarter 2008 GAAP net income fell to $69.6 million, ... $9.94 - Pharma Marketletter - Alacra Store Genzyme guidance upped on good 2nd qtr.(Brief Article) - Jul 25, 2005 Turnover of Cerezyme (imiglucerase for injection), for Type 1 Gaucher disease, was $236.0 million, up 13% on the same quarter last year. ... $4.95 - Pharma Marketletter - ECNext Pompe Disease; US FDA approves Genzyme's Myozyme for patients with … - Jun 1, 2006 Genzyme has developed Cerezyme (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme (agalsidase beta) for Fabry disease; and, in collaboration ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Genzyme's 2nd-qtr net income jumps 4%.(Financial report)(Brief... - Aug 6, 2007 US biotechnology major Genzyme's second-quarter 2007 profit totaled $139.9 million, or $0.51 per share, up 4% on the like, year-ago period, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Genyzyme's 3rd-qtr results beat forecasts with an 18% increase in... - Oct 24, 2005 Meanwhile, Cerezyme (imiglucerase for injection), which treats the rare enzyme deficiency Gaucher disease, saw its sales grow 14% to $238.2 million. ... $4.95 - Pharma Marketletter - ECNext Press Release: Genzyme Receives Approval for Additional Manufacturing... - Jul 24, 2006 Genzyme is currently conducting approval-qualifying manufacturing runs of Cerezyme(R) (imiglucerase for injection) and Myozyme(R) (alglucosidase alfa) at ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Genzyme Receives Approval to Market Elaprase(R) in … - Oct 4, 2007 The company also markets Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; ... Pay-Per-View - PR Newswire - HighBeam Research Pompe Disease; US FDA approves Genzyme's Myozyme for patients with … - May 29, 2006 Genzyme has developed Cerezyme (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme (agalsidase beta) for Fabry disease; and, in collaboration ... Pay-Per-View - Cardiovascular Week - Factiva, from Dow Jones Genzyme Reports Strong Third-Quarter Financial Results. - Oct 12, 2006 Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $252.2 million, 6 percent greater than sales of ... $4.95 - PR Newswire - ECNext Genzyme's 1st-qtr revenues up 28%.(Brief Article) - May 2, 2005 Turnover of Cerezyme (imiglucerase for injection), an enzyme replacement therapy for type 1 Gaucher disease, was $226.0 million, up 11%, while Aldurazyme ... $4.95 - Pharma Marketletter - ECNext Genzyme delivers 22% 4th-qtr 2005 revenue growth, just under … - Jan 16, 2006 Sales of Genzyme's enzyme replacement therapy for Type 1 Gaucher disease, Cerezyme (imiglucerase for injection), grew 6% to $232.0 million. ... $4.95 - Pharma Marketletter - ECNext Genzyme Announces Publication of Study and StemCells, Inc. Elects … - Jan 16, 2007 ...of the Journal of Bone and Mineral Research demonstrates that long-term use of Cerezyme (imiglucerase for injection) significantly improves bone mineral ... $4.95 - M2 Presswire - ECNext Press Release: Genzyme Announces Publication of Study and StemCells, … - Jan 16, 2007 ...of the Journal of Bone and Mineral Research demonstrates that long-term use of Cerezyme (imiglucerase for injection) significantly improves bone mineral ... Pay-Per-View - M2 Presswire - HighBeam Research Patents; Genzyme files patent infringement suit - Feb 25, 2005 Genzyme's patent covers novel culture processes that have been critical in enabling the company to produce Cerezyme (imiglucerase for injection) on a large ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Patents; Genzyme files patent infringement suit - Feb 22, 2005 Genzyme's patent covers novel culture processes that have been critical in enabling the company to produce Cerezyme (imiglucerase for injection) on a large ... Pay-Per-View - Science Letter - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |